“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials”, J of Skin, vol. 7, no. 4, p. s219, Jul. 2023, doi: 10.25251/skin.7.supp.219.